Skip to main content
Erschienen in: Clinical Rheumatology 10/2016

01.07.2016 | Original Article

Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data

verfasst von: Mirjana Bećarević, Svetlana Ignjatović

Erschienen in: Clinical Rheumatology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

The latest classification criteria for the diagnosis of the antiphospholipid syndrome (APS, an autoimmune disease characterized by thromboses, miscarriages and presence of antiphospholipid antibodies (Abs)) emphasized that thrombotic manifestations of APS should be without any signs of an inflammatory process. However, atherosclerosis (a chronic inflammatory response to the accumulation of lipoproteins in the walls of arteries) and APS are characterized by some similar features. We evaluated whether proinflammatory proteins were associated with the features of the primary APS (PAPS). PAPS patients without obstetric complications and with impaired lipid profile were included in the study. Antiphospholipid antibodies, TNF-alpha, and apo(a) were determined by ELISA. Complement components and hsCRP were measured by immunonephelometry. Decreased C3c was observed in female patients with increased titers of IgG anti-β2gpI (χ2 = 3.939, P = 0.047) and in male patients with increased IgM anticardiolipin Abs (χ2 = 4.286, P = 0.038). Pulmonary emboli were associated with interleukin (IL)-6 in male (χ2 = 6.519, P = 0.011) and in female (χ2 = 10.405, P = 0.001) patients. Cerebrovascular insults were associated with LDL-cholesterol (P = 0.05, 95 % CI: 1.003 - 12.739) in female and with apo(a) (P = 0.016, 95 % CI: 0.000–0.003) in male patients. Older female patients had increased LDL-cholesterol levels and frequency of myocardial infarctions. Proinflammatory proteins were associated with features of primary APS. No real gender differences in regard to proinflammatory protein levels were observed. Premenopausal state of female PAPS patients confers lower cardiovascular risk.
Literatur
1.
Zurück zum Zitat Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930CrossRefPubMed Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al (2014) 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930CrossRefPubMed
2.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306CrossRefPubMed
3.
Zurück zum Zitat Willis R, Gonzalez EB, Brasier AR (2015) The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep 17:16CrossRefPubMed Willis R, Gonzalez EB, Brasier AR (2015) The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep 17:16CrossRefPubMed
4.
Zurück zum Zitat Motoki Y, Nojima J, Yanagihara M et al (2012) Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thromb Res 130:667–673CrossRefPubMed Motoki Y, Nojima J, Yanagihara M et al (2012) Anti-phospholipid antibodies contribute to arteriosclerosis in patients with systemic lupus erythematosus through induction of tissue factor expression and cytokine production from peripheral blood mononuclear cells. Thromb Res 130:667–673CrossRefPubMed
5.
Zurück zum Zitat Broder A, Chan JJ, Putterman C (2013) Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin Immun 146:197–206CrossRef Broder A, Chan JJ, Putterman C (2013) Dendritic cells: an important link between antiphospholipid antibodies, endothelial dysfunction, and atherosclerosis in autoimmune and non-autoimmune diseases. Clin Immun 146:197–206CrossRef
6.
Zurück zum Zitat Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Wedenborg J, Fei GZ, Frostegard J (2005) Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203PubMed Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Wedenborg J, Fei GZ, Frostegard J (2005) Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203PubMed
7.
Zurück zum Zitat Medina G, Vera-Lastra O, Barile L, Salas M, Jara LJ (2004) Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: a comparative study of 73 patients. Lupus 13:11–16CrossRefPubMed Medina G, Vera-Lastra O, Barile L, Salas M, Jara LJ (2004) Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: a comparative study of 73 patients. Lupus 13:11–16CrossRefPubMed
8.
Zurück zum Zitat Jara LJ, Medina G, Vera-Lastra O, Barile L (2005) The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 14:607–612CrossRefPubMed Jara LJ, Medina G, Vera-Lastra O, Barile L (2005) The impact of gender on clinical manifestations of primary antiphospholipid syndrome. Lupus 14:607–612CrossRefPubMed
9.
Zurück zum Zitat Hovland A, Jonasson L, Garred P et al (2015) The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 241:480–494CrossRefPubMed Hovland A, Jonasson L, Garred P et al (2015) The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis 241:480–494CrossRefPubMed
10.
Zurück zum Zitat Artenjak A, Omersel J, Ahlin Grabnar P, Mlinaric-Rascan I, Shoenfeld Y, Sodin-Semrl S, Bozic B, Cucnik S (2015) Oxidatively altered IgG with increased immunoreactivity to b2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells. Lupus 24:448–462CrossRefPubMed Artenjak A, Omersel J, Ahlin Grabnar P, Mlinaric-Rascan I, Shoenfeld Y, Sodin-Semrl S, Bozic B, Cucnik S (2015) Oxidatively altered IgG with increased immunoreactivity to b2-glycoprotein I and its peptide clusters influence human coronary artery endothelial cells. Lupus 24:448–462CrossRefPubMed
11.
Zurück zum Zitat Bećarević M, Seferović J, Ignjatović S, Singh S, Majkić-Singh N (2011) Significant association of antiphospholipid antibodies and TNF-alpha: marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. Cytokine 55:301–306CrossRefPubMed Bećarević M, Seferović J, Ignjatović S, Singh S, Majkić-Singh N (2011) Significant association of antiphospholipid antibodies and TNF-alpha: marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. Cytokine 55:301–306CrossRefPubMed
12.
Zurück zum Zitat Bećarević M, Ignjatović S, Majkić-Singh N (2012) Deterioration of thromboses in primary antiphospholipid syndrome: TNF-alpha and anti-annexin A5 antibodies. Clin Lab 58:1079–1084PubMed Bećarević M, Ignjatović S, Majkić-Singh N (2012) Deterioration of thromboses in primary antiphospholipid syndrome: TNF-alpha and anti-annexin A5 antibodies. Clin Lab 58:1079–1084PubMed
13.
Zurück zum Zitat Cavazzana I, Manuela N, Irene C et al (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28:160–164CrossRefPubMed Cavazzana I, Manuela N, Irene C et al (2007) Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process? J Autoimmun 28:160–164CrossRefPubMed
14.
Zurück zum Zitat Barilla-LaBarca ML, Toder K, Furie R (2013) Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148:313–321CrossRefPubMed Barilla-LaBarca ML, Toder K, Furie R (2013) Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol 148:313–321CrossRefPubMed
15.
Zurück zum Zitat Chen M, Daha MR, Kallenberg CGM (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:276–286CrossRef Chen M, Daha MR, Kallenberg CGM (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:276–286CrossRef
16.
Zurück zum Zitat Bećarević M, Majkić-Singh N (2008) High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome. Clin Biochem 41:1449–1453CrossRefPubMed Bećarević M, Majkić-Singh N (2008) High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome. Clin Biochem 41:1449–1453CrossRefPubMed
17.
Zurück zum Zitat Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T et al (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030e5CrossRef Oku K, Atsumi T, Bohgaki M, Amengual O, Kataoka H, Horita T et al (2009) Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 68:1030e5CrossRef
18.
Zurück zum Zitat Barnes EV, Narin S, Naranjo A et al (2005) High-sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14:576–582CrossRefPubMed Barnes EV, Narin S, Naranjo A et al (2005) High-sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14:576–582CrossRefPubMed
19.
Zurück zum Zitat Matos MF, Lourenço DM, Orikaza CM, Bajerl JAH, Noguti MAE, Morelli VM (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6-174GC, IL-8-251AT and MCP-1-2518AG in the risk of venous thromboembolism: a case–control study. Thromb Res 128:216–220CrossRefPubMed Matos MF, Lourenço DM, Orikaza CM, Bajerl JAH, Noguti MAE, Morelli VM (2011) The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6-174GC, IL-8-251AT and MCP-1-2518AG in the risk of venous thromboembolism: a case–control study. Thromb Res 128:216–220CrossRefPubMed
20.
Zurück zum Zitat Folsom AR, Lutsey PL, Astor BC, Cushman M (2009) C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 102:615–619PubMedPubMedCentral Folsom AR, Lutsey PL, Astor BC, Cushman M (2009) C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost 102:615–619PubMedPubMedCentral
21.
Zurück zum Zitat Zacho J, Tybjaerg-Hansen A, Nordestgaard BG (2010) C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 30:1672–1678CrossRefPubMed Zacho J, Tybjaerg-Hansen A, Nordestgaard BG (2010) C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol 30:1672–1678CrossRefPubMed
22.
23.
Zurück zum Zitat Reitsma PH, Rosendaal FR (2004) Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2:619–622CrossRefPubMed Reitsma PH, Rosendaal FR (2004) Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2:619–622CrossRefPubMed
24.
Zurück zum Zitat Christiansen SC, Naess IA, Cannegieter SC, Hammerstrøm J, Rosendaal FR, Reitsma PH (2006) Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 3, e334CrossRefPubMedPubMedCentral Christiansen SC, Naess IA, Cannegieter SC, Hammerstrøm J, Rosendaal FR, Reitsma PH (2006) Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 3, e334CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Salobir B, Sabovic M (2004) Possible vascular-bed-specific role of interleukin-6 in young women with a history of myocardial infarction, lacunar cerebral infarction and deep vein thrombosis. Cytokine 25:265–272CrossRefPubMed Salobir B, Sabovic M (2004) Possible vascular-bed-specific role of interleukin-6 in young women with a history of myocardial infarction, lacunar cerebral infarction and deep vein thrombosis. Cytokine 25:265–272CrossRefPubMed
26.
Zurück zum Zitat Ames PR, Matsuura E, Batuca JR, Ciampa A, Lopez LL, Ferrara F et al (2010) High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 19:711–716CrossRefPubMed Ames PR, Matsuura E, Batuca JR, Ciampa A, Lopez LL, Ferrara F et al (2010) High-density lipoprotein inversely relates to its specific autoantibody favoring oxidation in thrombotic primary antiphospholipid syndrome. Lupus 19:711–716CrossRefPubMed
27.
Zurück zum Zitat Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ (2011) Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 10(4):214–217CrossRefPubMed Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ (2011) Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 10(4):214–217CrossRefPubMed
Metadaten
Titel
Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data
verfasst von
Mirjana Bećarević
Svetlana Ignjatović
Publikationsdatum
01.07.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 10/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3345-3

Weitere Artikel der Ausgabe 10/2016

Clinical Rheumatology 10/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.